Publications and Presentations
April 7, 2024
Synergistic Effect of Obicetrapib and Ezetimibe on Circulating LDL Particles
November 11, 2023
Obicetrapib as an Adjunct to Stable Statin Therapy Significantly Lowers LDL-C, Non-HDL-C and Apolipoprotein B in Japanese Patients: Results from the Japan Phase 2 Study
October 28, 2023
The Evolving Role of Cholesteryl Ester Transfer Protein Inhibition Beyond Cardiovascular Disease
June 3, 2023
The combination of obicetrapib and ezetimibe lowers LDL-C in patients on high-intensity statins: results from the ROSE2 Trial (NCT05266586)
May 20, 2023
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial (ROSE2)
August 11, 2022
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial (ROSE)
November 20, 2021
Cholesteryl ester transfer protein inhibitors: From high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
November 13, 2021
ROSE: A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose Finding Study to Evaluate the Effect of Obicetrapib 5 and 10 mg as an Adjunct to High-Intensity Statin Therapy
October 12, 2021
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
March 17, 2014